Global Chronic
Kidney Disease Drugs Market, by Drug Type (ACE Inhibitors, B-blockers,
Calcium Channel Blockers, Loop Diuretics, Erythropoiesis-stimulating Agents
(ESAs), Phosphate Binders, and Others), by Route of Administration (Oral,
Intravenous, and Subcutaneous), by Patient Type (Dialysis and Others), by Distribution
Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by
Region (North America, Latin America, Europe, Asia Pacific, Middle East, and
Africa), is estimated to be valued at US$ 12,328.2 million in 2020 and is
expected to exhibit a CAGR of 4.0% over the forecast period (2020-2027), as
highlighted in a new report published by Coherent Market Insights.
The increasing prevalence of
chronic kidney disease is expected to drive the market growth over the forecast
period. For instance, according to the Centers for Disease Control and
Prevention (CDC) estimations 2019, the chronic kidney disease is more common in
people of age 65 years or above and around 125,000 people in the U.S. started
treatment for end-stage kidney disease (ESKD) and over 726,000 (2 in every
1,000 people) in 2018 were on dialysis or were living with a kidney transplant.
Chronic kidney disease is the
progressive loss of kidney function over a period of several years. As kidney
failure advances to further stages, and the organ’s function is severely
impaired, dangerous levels of waste and fluid can rapidly build up in the body.
Early detection can help prevent the progression of kidney disease to kidney
failure. Heart disease is the major cause of death for people with CKD.
Treatment is aimed at stopping or slowing down the progression of the disease –
this is usually done by controlling its underlying cause. ACE Inhibitors,
B-blockers, Calcium Channel Blockers, and Erythropoiesis-stimulating Agents
(ESAs) are some of the major drug class used in the treatment of chronic kidney
disease or its underlying cause.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1713
Global Chronic Kidney Disease
Drugs Market – Impact of Coronavirus (Covid-19) Pandemic
The COVID-19 pandemic has
impacted the global economy and in turn, the chronic kidney disease drugs
market. Quarantine, traveling constraints, and social distancing measures are
likely to lead to a steep decline in business and consumer spending until the end
of the second quarter of 2020. Moreover, the COVID-19 pandemic has drastically
affected clinical trials. Many trials have paused enrollment and researchers
are facing multiple challenges associated with setting up remote visits, and
performing laboratory, and other study assessments.
Browse 44 Market Data Tables and
39 Figures spread through 206 Pages and in-depth TOC on “Chronic Kidney Disease
Drugs Market”- Global Forecast to 2027, by Drug Type (ACE Inhibitors,
B-Blockers, Calcium Channel Blockers, Loop Diuretics,
Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, and Others), by
Route of Administration (Oral, Intravenous, and Subcutaneous), by Patient Type
(Dialysis and Others), by Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, and Online Pharmacies), and by Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa),
Furthermore, product approvals
and launches for the treatment of chronic kidney disease are expected to drive
the market growth over the forecast period. For instance, in November 2018,
Kissei Pharmaceutical Co., Ltd. launched P-TOL Granules (250 mg and 500 mg)
tablets indicated for the treatment of hyperphosphatemia in patients with
chronic kidney disease on dialysis. Moreover, in June 2019, Reata
Pharmaceuticals, Inc. received the orphan drug designation from the U.S. Food
and Drug Administration (FDA) for bardoxolone methyl (bardoxolone) indicated
for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/chronic-kidney-disease-drugs-market-1713
Key Takeaways of the Global
Chronic Kidney Disease Drugs Market:
The global chronic kidney disease
drugs market is expected to exhibit a CAGR of 4.0% during the forecast period,
owing to growing prevalence of chronic kidney disease and increasing approvals
& launches of novel drugs for the treatment of chronic kidney disease. For
instance, according to Lancet data, prevalence of chronic kidney disease in
Western Europe was estimated at 41,976,625 patients in 2017.
Among drug type,
erythropoiesis-stimulating agents (ESAs) segment is estimated to hold a dominant
position in the global chronic kidney disease drugs market in 2020, owing to
recent launches of novel products by key players. For instance, For instance,
in May 2018, Pfizer Inc. received approval from the U.S. Food and Drug
Administration (FDA) for Retacrit, a biosimilar to Epogen and Procrit (epoetin
alfa) by Amgen Inc.
On the basis of route of
administration, intravenous segment is estimated to hold a dominant position in
the global chronic kidney disease drugs market in 2020 due to increasing regulatory
approval for intravenous drugs, faster action, and robust pipeline of
intravenous products. For instance, For instance, in February 2017, Amgen, Inc.
received approval from the U.S. Food and Drug Administration (FDA) for Parsabiv
(etelcalcetide), indicated for the treatment of secondary hyperparathyroidism
(sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis
In terms of patient type,
dialysis segment is estimated to account for major market share in 2020 due to
rise in number of patients suffering from end-stage renal disease, growing
number of dialysis procedures & treatment centers, and increasing research
activities seeking treatment options for dialysis patients. For instance,
According to 2018 annual report of the U.S Renal Data System (USRDS), around
750,000 patients per year in the U.S. are affected by kidney failure, which is
also called end stage renal disease (ESRD). Moreover, according to the same
source, around 2 million people worldwide suffer from ESRD every year.
Among distribution channel,
hospital pharmacies segment dominated the global chronic kidney disease drugs
market in 2020, owing to increasing number of patient admission in hospitals
due to chronic kidney disease, and partnerships & agreements of hospitals with
specialty pharmacies services providers. For instance, according to one of the
articles published in WebMD LLC., in 2018, emergency department visits due to
end-stage renal disease (ESRD) increased to an average of 3 per patient per
year in the U.S.
Among regions, North America is
estimated to hold largest market share in the global chronic kidney disease
drugs market in 2020, owing to higher prevalence of chronic kidney disease and
end-stage renal disease, and presence of higher number of patients with high
blood pressure and diabetes in the region, which are leading causes of chronic
kidney disease. For instance, according to CDC, high blood pressure and
diabetes are leading causes of chronic kidney disease. Currently, approximately
1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure might
have chronic kidney disease in the U.S.
Key players operating in the
global chronic kidney disease drugs market include Amgen, Inc., Teva
Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, Hoffmann La Roche
Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., Reata
Pharmaceuticals, Inc., GlaxoSmithKline Plc, and Ardelyx, Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1713
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
